These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32327165)

  • 1. Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim.
    Socal MP; Anderson KE; Sen A; Bai G; Anderson GF
    Value Health; 2020 Apr; 23(4):481-486. PubMed ID: 32327165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uptake and cost of biosimilar filgrastim among Medicare and Medicaid populations in 2015-2018.
    Qian J
    J Manag Care Spec Pharm; 2021 May; 27(5):660-666. PubMed ID: 33908273
    [No Abstract]   [Full Text] [Related]  

  • 3. Physician, Practice, and Patient Characteristics Associated With Biosimilar Use in Medicare Recipients.
    Dean EB; Johnson P; Bond AM
    JAMA Netw Open; 2021 Jan; 4(1):e2034776. PubMed ID: 33502485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Filgrastim and infliximab biosimilar uptake in Medicare Advantage compared with Traditional Medicare, 2016-2019.
    Liu A; Xuan A; Socal M; Anderson G; Anderson KE
    J Manag Care Spec Pharm; 2024 Jan; 30(1):15-21. PubMed ID: 38153867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilar Filgrastim Uptake And Costs Among Commercially Insured, Medicare Advantage.
    Karaca-Mandic P; Chang J; Go R; Schondelmeyer S; Weisdorf D; Jeffery MM
    Health Aff (Millwood); 2019 Nov; 38(11):1887-1892. PubMed ID: 31682491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim.
    Grewal S; Ramsey S; Balu S; Carlson JJ
    Expert Rev Pharmacoecon Outcomes Res; 2018 Aug; 18(4):447-454. PubMed ID: 29757040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-Administered Biologic and Biosimilar Filgrastim May Offer More Affordable Options for Patients with Nonmyeloid Malignancies Receiving Chemotherapy in the United States: A Budget Impact Analysis from the Payer Perspective.
    Trautman H; Szabo E; James E; Tang B
    J Manag Care Spec Pharm; 2019 Jan; 25(1):94-101. PubMed ID: 30084301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Provider differences in biosimilar uptake in the filgrastim market.
    Chen AJ; Ribero R; Van Nuys K
    Am J Manag Care; 2020 May; 26(5):208-213. PubMed ID: 32436678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion from Filgrastim to Tbo-filgrastim: Experience of a Large Health Care System.
    Agboola F; Reddy P
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1214-1218. PubMed ID: 29172977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy.
    Schwartzberg LS; Lal LS; Balu S; Campbell K; Brekke L; DeLeon A; Elliott C; Korrer S
    J Manag Care Spec Pharm; 2018 Oct; 24(10):976-984. PubMed ID: 29687743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comparison of Brand and Biosimilar Granulocyte-Colony Stimulating Factors for Prophylaxis of Chemotherapy-Induced Febrile Neutropenia.
    Douglas AG; Schwab P; Lane D; Kennedy K; Slabaugh SL; Bowe A
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1221-1226. PubMed ID: 29172983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia.
    McBride A; Campbell K; Bikkina M; MacDonald K; Abraham I; Balu S
    J Med Econ; 2017 Oct; 20(10):1083-1093. PubMed ID: 28722494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding utilization patterns of biologics and biosimilars in the United States to support postmarketing studies of safety and effectiveness.
    Dutcher SK; Fazio-Eynullayeva E; Eworuke E; Carruth A; Dee EC; Blum MD; Nguyen MD; Toh S; Panozzo CA; Lyons JG
    Pharmacoepidemiol Drug Saf; 2020 Jul; 29(7):786-795. PubMed ID: 31828887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma.
    McBride A; Krendyukov A; Mathieson N; Campbell K; Balu S; Natek M; MacDonald K; Abraham I
    J Med Econ; 2020 Jan; 23(1):28-36. PubMed ID: 31433700
    [No Abstract]   [Full Text] [Related]  

  • 15. Site of care potentially limits cost savings from biosimilars.
    Chang J; Karaca-Mandic P; Go RS; Schondelmeyer S; Weisdorf D; Jeffery MM
    Am J Manag Care; 2021 Aug; 27(8):e287-e289. PubMed ID: 34460183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.
    Chen B; Nagai S; Armitage JO; Witherspoon B; Nabhan C; Godwin AC; Yang YT; Kommalapati A; Tella SH; DeAngelis C; Raisch DW; Sartor O; Hrushesky WJ; Ray PS; Yarnold PR; Love BL; Norris LB; Knopf K; Bobolts L; Riente J; Luminari S; Kane RC; Hoque S; Bennett CL
    Oncologist; 2019 Apr; 24(4):537-548. PubMed ID: 30842244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products.
    Mouslim MC; Trujillo AJ; Alexander GC; Segal JB
    Value Health; 2020 Dec; 23(12):1599-1605. PubMed ID: 33248515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives.
    Baker JF; Leonard CE; Lo Re V; Weisman MH; George MD; Kay J
    Arthritis Rheumatol; 2020 Jul; 72(7):1067-1071. PubMed ID: 32253823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of the FDA Biosimilar Extrapolation Framework to Make Off-Label Determinations.
    Li E; Lobaina E
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1227-1232. PubMed ID: 29172978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz.
    McBride A; Balu S; Campbell K; Bikkina M; MacDonald K; Abraham I
    Future Oncol; 2017 Oct; 13(25):2285-2295. PubMed ID: 28870106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.